EP2486054A4 - Recombinant antibodies against h1n1 influenza - Google Patents

Recombinant antibodies against h1n1 influenza

Info

Publication number
EP2486054A4
EP2486054A4 EP10822829.7A EP10822829A EP2486054A4 EP 2486054 A4 EP2486054 A4 EP 2486054A4 EP 10822829 A EP10822829 A EP 10822829A EP 2486054 A4 EP2486054 A4 EP 2486054A4
Authority
EP
European Patent Office
Prior art keywords
influenza
antibodies against
recombinant antibodies
recombinant
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10822829.7A
Other languages
German (de)
French (fr)
Other versions
EP2486054A2 (en
Inventor
Jens Wrammert
Rafi Ahmed
Patrick Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Emory University
Original Assignee
University of Chicago
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago, Emory University filed Critical University of Chicago
Publication of EP2486054A2 publication Critical patent/EP2486054A2/en
Publication of EP2486054A4 publication Critical patent/EP2486054A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP10822829.7A 2009-10-09 2010-10-12 Recombinant antibodies against h1n1 influenza Withdrawn EP2486054A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25047909P 2009-10-09 2009-10-09
US26065009P 2009-11-12 2009-11-12
PCT/US2010/052274 WO2011044570A2 (en) 2009-10-09 2010-10-12 Recombinant antibodies against h1n1 influenza

Publications (2)

Publication Number Publication Date
EP2486054A2 EP2486054A2 (en) 2012-08-15
EP2486054A4 true EP2486054A4 (en) 2013-09-11

Family

ID=43857434

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10822829.7A Withdrawn EP2486054A4 (en) 2009-10-09 2010-10-12 Recombinant antibodies against h1n1 influenza

Country Status (3)

Country Link
US (1) US9458226B2 (en)
EP (1) EP2486054A4 (en)
WO (1) WO2011044570A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2486054A4 (en) 2009-10-09 2013-09-11 Univ Emory Recombinant antibodies against h1n1 influenza
CA2852474A1 (en) 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
DE102012010209A1 (en) 2012-05-18 2013-11-21 Universität Leipzig Enrichment of antigen-specific memory-B cells for production of recombinant monoclonal antibodies, comprises magnetic separation with magnetic-bound antigen, from the blood of vertebrates e.g. humans
CN105051062A (en) * 2013-03-15 2015-11-11 王慧茹 Biological therapeutics for infection-relating disorders or conditions
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2009115972A1 (en) * 2008-03-17 2009-09-24 Pomona Biotechnologies Llc Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337070B1 (en) * 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
JP2996864B2 (en) 1994-03-30 2000-01-11 寳酒造株式会社 Antibody variable region DNA
EP2486054A4 (en) 2009-10-09 2013-09-11 Univ Emory Recombinant antibodies against h1n1 influenza
CA2852474A1 (en) 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2009115972A1 (en) * 2008-03-17 2009-09-24 Pomona Biotechnologies Llc Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
NAKAJIMA S ET AL: "Identification of the binding sites to monoclonal antibodies on A/USSR/90/77 (H1N1) hemagglutinin and their involvement in antigenic drift in H1N1 influenza viruses", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 131, no. 1, 1 November 1983 (1983-11-01), pages 116 - 127, XP023058258, ISSN: 0042-6822, [retrieved on 19831101], DOI: 10.1016/0042-6822(83)90538-X *
SHEERAR M G ET AL: "ANTIGENIC CONSERVATION OF H1N1 SWINE INFLUENZA VIRUSES", JOURNAL OF GENERAL VIROLOGY, vol. 70, no. 12, 1989, pages 3297 - 3304, XP002707590, ISSN: 0022-1317 *
VARECKOVÁ EVA ET AL: "Evaluation of the subtype specificity of monoclonal antibodies raised against H1 and H3 subtypes of human influenza A virus hemagglutinins.", JOURNAL OF CLINICAL MICROBIOLOGY JUN 2002, vol. 40, no. 6, June 2002 (2002-06-01), pages 2220 - 2223, XP002707585, ISSN: 0095-1137 *
WENTWORTH DAVID E ET AL: "An influenza A (H1N1) virus, closely related to swine influenza virus, responsible for a fatal case of human influenza", JOURNAL OF VIROLOGY, vol. 68, no. 4, 1994, pages 2051 - 2058, XP002707584, ISSN: 0022-538X *
WRAMMERT JENS ET AL: "Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 208, no. 1, January 2011 (2011-01-01), pages 181 - 193, XP002707586, ISSN: 0022-1007 *
YAMASHITA A ET AL: "Highly conserved sequences for human neutralization epitope on hemagglutinin of influenza A viruses H3N2, H1N1 and H5N1: Implication for human monoclonal antibody recognition", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 393, no. 4, 19 March 2010 (2010-03-19), pages 614 - 618, XP026970727, ISSN: 0006-291X, [retrieved on 20100210], DOI: 10.1016/J.BBRC.2010.02.031 *

Also Published As

Publication number Publication date
WO2011044570A2 (en) 2011-04-14
US9458226B2 (en) 2016-10-04
EP2486054A2 (en) 2012-08-15
WO2011044570A3 (en) 2011-09-29
US20120282273A1 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
HK1154041A1 (en) Soluble recombinant influenza antigens
EP2501423A4 (en) Nasal interface
EP2518338A4 (en) Clip
GB0810305D0 (en) Influenza vaccination
SG10201403557QA (en) Swine influenza hemagglutinin variants
PL2358386T3 (en) Optimized influenza vaccines
ZA201205066B (en) Clip connection
EP2428690A4 (en) Clip
EP2416020A4 (en) Clip
EP2486054A4 (en) Recombinant antibodies against h1n1 influenza
IL214257A0 (en) Peptides for vaccine
GB0918679D0 (en) Influenza vaccine
EP2405149A4 (en) Clip
HK1168795A1 (en) Assays for influenza virus hemagglutinins
ZA201100962B (en) Influenza vaccines
EP2435476A4 (en) Avian derived antibodies
SG10201404566XA (en) Viral advertisements
SI2482845T1 (en) Novel vaccine composition against influenza
ZA201108446B (en) FViII-DERIVED PEPTIDES
EP2471915A4 (en) Modified peptide vaccine derived from influenza m2
GB0912950D0 (en) Virus
EP2444330A4 (en) Clip
EP2424879A4 (en) Influenza vaccine
GB0901056D0 (en) Virus
HK1177692A1 (en) Novel influenza virus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120329

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1174646

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/42 20060101ALI20130731BHEP

Ipc: C12N 15/13 20060101ALI20130731BHEP

Ipc: A61P 31/16 20060101ALI20130731BHEP

Ipc: C07K 16/10 20060101AFI20130731BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20130809

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140307